Zoetis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Zoetis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. 

CEO
Kristin C. Peck
CEOKristin C. Peck
Employees
14,500
Employees14,500
Headquarters
Parsippany, New Jersey
HeadquartersParsippany, New Jersey
Founded
1952
Founded1952
Employees
14,500
Employees14,500

ZTS Key Statistics

Market cap
50.96B
Market cap50.96B
Price-Earnings ratio
19.62
Price-Earnings ratio19.62
Dividend yield
1.72%
Dividend yield1.72%
Average volume
3.81M
Average volume3.81M
High today
$120.83
High today$120.83
Low today
$118.66
Low today$118.66
Open price
$118.66
Open price$118.66
Volume
242.86K
Volume242.86K
52 Week high
$172.23
52 Week high$172.23
52 Week low
$114.47
52 Week low$114.47

Stock Snapshot

The current Zoetis(ZTS) stock price is $120.71, with a market capitalization of 50.96B. The stock trades at a price-to-earnings (P/E) ratio of 19.62 and offers a dividend yield of 1.7%.

As of 2026-03-17, Zoetis(ZTS) stock has fluctuated between $118.66 and $120.83. The current price stands at $120.71, placing the stock +1.7% above today's low and -0.1% off the high.

Zoetis(ZTS) shares are trading with a volume of 242.86K, against a daily average of 3.81M.

In the last year, Zoetis(ZTS) shares hit a 52-week high of $172.23 and a 52-week low of $114.47.

In the last year, Zoetis(ZTS) shares hit a 52-week high of $172.23 and a 52-week low of $114.47.

ZTS News

Simply Wall St 9h
Will Librela Safety Scrutiny and Guidance Cut Change Zoetis' Long-Term Narrative?

In recent weeks, Zoetis Inc. has faced renewed scrutiny over its osteoarthritis drug Librela, with management cutting full-year guidance and committing to provi...

Will Librela Safety Scrutiny and Guidance Cut Change Zoetis' Long-Term Narrative?
Simply Wall St 2d
A Look At Zoetis Valuation As Investor Visibility And Fundamentals Draw Fresh Attention

Advertisement Why Zoetis (ZTS) Is Back on Investor Radars Zoetis (ZTS) has been drawing fresh attention as management steps into multiple healthcare conferenc...

A Look At Zoetis Valuation As Investor Visibility And Fundamentals Draw Fresh Attention
Simply Wall St 5d
Zoetis Backs Vet Tech Training To Deepen Long Term Clinic Ties

Zoetis (NYSE:ZTS) is expanding its support for veterinary education by offering free Human Animal Bond Certification to veterinary technician students across th...

Zoetis Backs Vet Tech Training To Deepen Long Term Clinic Ties

Analyst ratings

61%

of 23 ratings
Buy
60.9%
Hold
39.1%
Sell
0%

People also own

Based on the portfolios of people who own ZTS. This list is generated using Robinhood data, and it’s not a recommendation.
Visa
Costco
Microsoft
UnitedHealth
Palo Alto Networks
Salesforce

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.